Abstract Details

�鶹��ýӳ��

Abstract Details

Title Micro RNAs (miRNA) Disregulation in Multiple Sclerosis Related Cognitive Impairment; pilot study

Topic Multiple Sclerosis

Presentation(s) P10 - Poster Session 10 (5:30 PM-6:30 PM)

Poster/Presentation
Number 9-017

Objective

Compare people with MS (pwMS) with (wCI) and without (woCI) cognitive impairment(CI) on expression of

1) hypothesized miRNAs -9, -34, -34a, -124, -125, -125b, - miR-146, -146a, -155, -181c in CSF and plasma

2) all other miRNAs sequences in CSF and plasma

3) messenger RNA in CSF

4) using s network-visualization method for gene-set enrichment to build a network crosstalk map of enriched pathways

Background 40 to 60% of pwMS have CI leading to loss of employment, functional decline, and social isolation. miRNA's are small RNA that regulate gene expression. Few data exist on the relation of miRNAs and CI in MS. Our study focused on MiRs -9, -34, -34a, -124, -125, -125b, - miR-146, -146a, -155, -181c as these MiRNA’s are dysregulated in MS and in AD.

Design/Methods 26 pwMS, >18 years old, (EDSS) ≤ 6.5, participated, 14 wCI and 12 woCI. wCI defined as a score ≥ 1.5 SD and woCI as <1 SD standardized neuropsychological tests (sNST). LC Sciences (Houston TX, USA) analyzed cell free CSF (6 wCI, 8 wCI) and plasma (14wCI and 12 woCI) using Illumina's Truseq™ Small RNA isolation, Cluster Station sequencing and Sequencing Control Studio( v2.8) and Real-Time Analysis version 1.8.70 (RTA v1.8.70).

Results

1)A priory selected miRNA: In CSF hsa-miR-146b-5p (all p<0.05) were lower in CI vs non-CI group. miR hsa-miR-9-3p (p< 0.05) was higher in CI vs non-CI group. Plasma showed no differences.

2) All miRNA: In CSF, hsa-miR-30e-5p, hsa-miR-122-5p, hsa-miR-30c-5p (all p<0.01) were lower in CI vs non-CI group.

3) RNA: ASIC2, RILPL1, LINC00211 (all p<1E-6) were higher in CI vs non-CI group CSF. No differences in plasma.

Conclusions CSF miRNA are more informative than plasma. miRNA related to neuronal progenitor and microglial activation are dysregulated in people with MS. CSF is more informative than plasma.

Authors/Disclosures
Jesus Lovera, MD (LSUHSC-New Orleans) PRESENTER	Dr. Lovera has nothing to disclose.
Deidre J. Devier, PhD	No disclosure on file
	No disclosure on file
Vivian R. Jaber, MD, PhD (Vivian R. Jaber)	No disclosure on file
	No disclosure on file